Trial: 202102176

A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Phase

I

Principal Investigator

Ghobadi, Armin

Disease Site

Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov